Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFNαR2a

Journal of Interferon and Cytokine Research

Volumn 34, Issue 1, 2014, Pages 28-34

  Lee, Yu Jin ^a   Zhang, Xiaozhen ^a   Vazquez, Estefania ^a   Shivasabesan, Gayathri ^a   Young, Howard A ^b   Murphy, Alison ^a   Wang, Honghui ^c   Suffredini, Anthony F ^c   Siebenlist, Ulrich ^a   Kottilil, Shyam ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA INTERFERON; INTERFERON ALPHA 2 A RECEPTOR; JANUS KINASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; STAT PROTEIN; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; IFNAR2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG COMPETITION; DRUG INHIBITION; GENE EXPRESSION; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER; LYMPH NODE; MIXED INFECTION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEOMICS; SIGNAL TRANSDUCTION; SPLEEN; VIRAL CLEARANCE; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECTS; HEPACIVIRUS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; TRANSGENIC MOUSE; VIROLOGY;

ANIMALS; COINFECTION; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTOR, INTERFERON ALPHA-BETA; RIBAVIRIN; SIGNAL TRANSDUCTION;

EID: 84892169632     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0032     Document Type: Article

References (24)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341(8):556-562
2. Ambrus JL, Sr., Dembinski W, Ambrus JL, Jr., Sykes DE, Akhter S, Kulaylat MN, Islam A, Chadha KC. 2003. Free interferonalpha/ beta receptors in the circulation of patients with adenocarcinoma. Cancer 98(12):2730-2733
3. Bergamaschi C, Jalah R, Kulkarni V, Rosati M, Zhang GM, Alicea C, Zolotukhin AS, Felber BK, Pavlakis GN. 2009. Secretion and biological activity of short signal peptide IL-15 is chaperoned by IL-15 receptor alpha in vivo. J Immunol 183(5):3064-3072
4. Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C, Zhang GM, Patel V, Felber BK, Pavlakis GN. 2008. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem 283(7):4189-4199
5. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, Heathcote J, Edwards AM, McGilvray ID. 2005. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128(5):1437-1444
6. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C. 2004. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351(5):451-459
7. de Weerd NA, Samarajiwa SA, Hertzog PJ. 2007. Type I interferon receptors: Biochemistry and biological functions. J Biol Chem 282(28):20053-20057
8. Fernandez-Botran R. 1991. Soluble cytokine receptors: Their role in immunoregulation. FASEB J 5(11):2567-2574
9. Fields BN, Knipe DM, Howley PM. 2007. Fields Virology. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia
10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975-982
11. Hardy MP, Owczarek CM, Trajanovska S, Liu X, Kola I, Hertzog PJ. 2001. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 97(2):473-482
12. Jones SA, Richards PJ, Scheller J, Rose-John S. 2005. IL-6 transsignaling: The in vivo consequences. J Interferon Cytokine Res 25(5):241-253
13. Lempicki RA, Polis MA, Yang J, McLaughlin M, Koratich C, Huang DW, Fullmer B, Wu L, Rehm CA, Masur H, Lane HC, Sherman KE, Fauci AS, Kottilil S. 2006. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: Class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 193(8):1172-1177
14. Liu SY, Sanchez DJ, Cheng G. 2011. New developments in the induction and antiviral effectors of type I interferon. Curr Opin Immunol 23(1):57-64
15. Meng XW, Chi BR, Chen LG, Zhang LL, Zhuang Y, Huang HY, Sun X. 2005. Expression of interferon-Alpha/beta receptor protein in liver of patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol 11(25):3962-3965
16. Mizukoshi E, Kaneko S, Kaji K, Terasaki S, Matsushita E, Muraguchi M, Ohmoto Y, Kobayashi K. 1999. Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C. Hepatology 30(5):1325-1331
17. Muir AJ, Bornstein JD, Killenberg PG. 2004. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350(22):2265-2271
18. Novick D, Cohen B, Rubinstein M. 1992. Soluble interferonalpha receptor molecules are present in body fluids. FEBS Lett 314(3):445-448
19. Owczarek CM, Hwang SY, Holland KA, Gulluyan LM, Tavaria M, Weaver B, Reich NC, Kola I, Hertzog PJ. 1997. Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2. J Biol Chem 272(38):23865-23870
20. Poordad F, Dieterich D. 2012. Treating hepatitis C: Current standard of care and emerging direct-Acting antiviral agents. J Viral Hepat 19(7):449-464
21. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, Sprent J. 2006. Converting IL-15 to a superagonist by binding to soluble IL-15Ra. Proc Natl Acad Sci U S A 103(24):9166-9171
22. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH. 2008. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105(19):7034-7039
23. Schindler C, Levy DE, Decker T. 2007. JAK-STAT signaling: From interferons to cytokines. J Biol Chem 282(28):20059-20063
24. Zhang X, Frank AC, Gille CM, Daucher M, Kabat J, Becker S, Lempicki RA, Cortez KJ, Polis MA, Subramanian GM, Kottilil S. 2009. Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis. Hepatol Res 39(12): 1178-1189